Avanos Medical, Inc. · NYSE:AVNS
Avanos Medical — JP Morgan Healthcare Conference 2026
23 slides from Avanos Medical's conference presentation, Jan 13, 2026
Slide 1: JP Morgan Healthcare Conference 2026
JP Morgan Healthcare Conference 2026 Dave Pacitti, Chief Executive Officer Getting patients back to what matters 1
Slide 2: Forward-looking statements
Certain matters in this presentation, including expectations and planning assumptions, any comments about our expected performance, and any estimates, projections, or statements relating to our business plans, objectives, acquisitions and transformation initiatives, constitute “forward-looking state
Slide 3: Investment Rationale
Solid mid-single digit organic growth profile Market leading positions with established reimbursement Expanding global direct sales organization Recently appointed CEO executing on company strategic imperatives Attractive M&A pipeline presents growth opportunities Strong balance sheet to support cap
Slide 4: Leading the Next Chapter at Avanos
Leading the Next Chapter at Avanos 4 Dave Pacitti Chief Executive Officer, Avanos Medical •30+ years of healthcare leadership •Former President, Siemens Medical Solutions USA & Head of the Americas, Siemens Healthineers •Former Division VP, Abbott Vascular; led major interventional product launches
Slide 5: Company Snapshot
Company Snapshot $690-$700M Net Sales With combined MSD growth in our strategic segments $0.85-$0.95 Adjusted EPS Range Reflecting $18M of tariff headwinds Balance Sheet Leverage Below 0.5x 2,200+ Employees Globally >50% across 5 manufacturing sites in the US, Canada and Mexico 5 Specialty Nutrition
Slide 6: SNS Segment: Three Nutrition Portfolios
Enteral feeding solutions for long-term nutritional support at home or in care facilities Long-Term Feeding 6 Short-Term Feeding Enteral feeding solutions designed for acute care patients who are unable to eat orally Neonatal Solutions Neonatal feeding and medication delivery solutions designed for
Slide 7: Short-Term Feeding current and future products
7 CURRENT PRODUCTS FUTURE PRODUCTS Short-Term Feeding Medication crushing device Pump & giving set Intelligent Feeding Nutrition Delivery System CORFLO* & CORTRAK* Nasoenteric Tubes CORGRIP* & ANCORIS* Securement CORTRAK* 2 Initial Placement System Extension Sets
Slide 8: Long-Term Feeding current and future products
8 Portable Nutrition Delivery System Specialized Blended Nutrition Pumps & Giving Sets Extension Sets MIC-KEY* Feeding Tubes CURRENT PRODUCTS FUTURE PRODUCTS Syringes MIC-KEY* Cares App Long-Term Feeding
Slide 9: Neonatal Solutions current and future products
9 Specialty Nutrition, Fortifier & Analysis Lipid-Saving Technology Intelligent Feeding Tube Placement & Confirmation Gastric Decompression Milk Tracking & Analysis System Milk Collection Bottles NEOMED* Enteral Syringes CURRENT PRODUCTS FUTURE PRODUCTS NEOMED* NG & Percutaneous Feeding Tubes TKO* M
Slide 10: Baby Noah's Miraculous Journey
• Born weighing just 2 pounds • Initially supported with an NG tube • Required additional nutritional support after discharge • MIC-KEY G tube placed by a pediatric surgeon • Appetite improved and G tube removed at age 2 • Now 6 years old and thriving in first grade Baby Noah’s Miraculous Journey 10
Slide 11: SNS Portfolio Growth Outlook: Above Market
11 SNS Portfolio Growth Outlook: Above Market Long-Term Feeding Neonatal SolutionsShort-Term Feeding Market Size Market Growth MIC-KEY* NEOMED*/TKO*CORTRAK*/CORFLO* Market size is US-only $500M $220M$300M 4-6% CAGR 4-6% CAGR 5-7% CAGR Market size is US-only Market size is US-onlyMarket size is US-on
Slide 12: SNS Pipeline
SNS Pipeline Short-term Feeding Neonatal Solutions Gastric Decompression Lipid Loss Prevention Next-Gen MIC-KEY* Next-Gen Pump & Sets Pump & SetsNext-Gen CORTRAK* Next-Gen Nutrition Delivery 1-2 years to Market 3-4 years to Market 5+ years to Market Blended Food Nutrition Adjacencies being evaluated
Slide 13: Nexus Medical Acquisition
Nexus Medical Acquisition 13 Strategic Rationale • Closed Sept. 15, 2025 • Maker of TKO® anti-reflux connector • Intended for safer delivery in NICU/PICU • Strong synergy with Avanos SNS • Global distribution • Established hospital relationships • Complementary clinical channels Financial & Growth I
Slide 14: PM&R Segment: Three Pain Management Portfolios
Non-opioid pain pumps enabling superior post-op pain control and opioid reduction† Surgical Pain ReliefRadiofrequency Ablation (RFA) RFA specialist with three-tier portfolio: ESENTEC, TRIDENT, and COOLIEF systems Recovery Cold compression therapy system for orthopedic procedure and athletic recovery
Slide 15: PM&R current and future products
15 TRIDENT* Tined Radiofrequency Nerve Ablation CURRENT PRODUCTS FUTURE PRODUCTS Procedural Needles, Kits & Trays Radiofrequency Ablation ON-Q* Elastomeric Infusion Pumps ambIT* Electronic Infusion Pumps Game Ready* Cold Compression Therapy Surgical Pain Relief Recovery Basivertebral Nerve Ablation
Slide 16: PM&R Portfolio Growth Outlook: At Market
16 PM&R Portfolio Growth Outlook: At Market Surgical Pain Relief $320M Flat CAGR Recovery $300M 6-8% CAGR $380M 3-5% CAGR Radiofrequency Ablation Market Size Market Growth ON-Q/ambIT* GAME READY*ESENTEC/TRIDENT/COOLIEF* Market size is US-only
Slide 17: PM&R Pipeline
PM&R Pipeline Radiofrequency Ablation Recovery 1-2 years to Market 3-4 years to Market 5+ years to Market HIFU BVNA Electrical Stimulation Nerve Block Iceless Game Ready <$100M >$1B Total Available Market Investment/ Partnership R&D Innovation Type 17
Slide 18: Expanding Global Sales Organization
Expanding Global Sales Organization 18 LATAM 12 employees 17 distributors APAC 58 employees 59 distributors EMEA 51 employees 70 distributors NA 275 employees 3 distributors As of Q4 2025
Slide 19: Our Vision & Strategic Imperatives
19 Accelerate growth in our strategic segments Find synergistic M&A opportunities Improve or divest underperforming assets Realize more operating efficiencies Mitigate the impact of tariffs Our Vision & Strategic Imperatives VISION: Path to $1B in revenue by 2030 through Five Strategic Imperatives
Slide 20: Priority Initiatives Enabling Our Path to $1B
20 Mitigate the impact of tariffs Realize more operating efficiencies Find synergistic M&A opportunities Improve or divest underperforming assets •Pricing optimization •Pursue exemptions •Complete China exit •Continue SKU rationalization •Exit low-margin/growth products Accelerate growth in our stra
Slide 21: Financial Highlights
Financial Highlights • Mid-single digit growth in strategic segments • Balance sheet capacity for M&A • ~$18M tariff headwind in 2025 • Driven by China and Mexico sourcing • Tariff Mitigation actions: • Exit China neonatal syringe production by mid-2026 • Strategic pricing and cost optimization • Co
Slide 22: Summary
Summary 22 Solid organic growth profile Market leading positions with established reimbursement Focused on executing company strategic imperatives M&A pipeline presents opportunities to accelerate growth Strong balance sheet
Slide 23: Investor Day 2026
INVESTOR DAY 2026 Join us in New York City! 23 June 23, 2026 CONVENE 101 Park Avenue, New York, NY
Avanos Medical — JP Morgan Healthcare Conference 2026 on 6ix